Will Adagio's COVID Antibody Therapy Be Too Late to the Party?

·3-min read

Adagio Therapeutics (NASDAQ: ADGI) plans to file for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration for its COVID-19 antibody therapy in the second quarter of 2022. In this Motley Fool Live video recorded on Nov. 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Adagio might be too late to the party with this regulatory filing.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting